mezigdomide 降解 Ikaros 减轻 T 细胞功能障碍并提高抗骨髓瘤 T 细胞疗法疗效
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.
95.9分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
FRONTIER PAPERS
前沿论文 16
BCMA 靶向治疗后复发/难治性多发性骨髓瘤患者中 teclistamab 的疗效和安全性
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
65.5分
★★★☆☆
站内排序·非疗效
仅仅是触及表面：靶向细胞膜蛋白的多发性骨髓瘤新型治疗方法
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.
64.0分
★★★☆☆
站内排序·非疗效
多发性骨髓瘤 CAR-T 细胞治疗的全球趋势：2013-2025 年文献计量学分析
Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025.
63.5分
★★★☆☆
站内排序·非疗效
其他 BCMA 靶向药物治疗后进展的多发性骨髓瘤患者接受 cilta-cel 的疗效和安全性
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
62.9分
★★★☆☆
站内排序·非疗效
多发性骨髓瘤中 BCMA 和 GPRC5D 靶向 CAR-T 细胞治疗应答的患者特异性决定因素：基于临床试验与真实世界数据的 QSP 分析
Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Re
57.9分
★★★☆☆
站内排序·非疗效
WVT078，一种 BCMA × CD3 双特异性抗体的临床前发现和初步临床数据
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
47.2分
★★★☆☆
站内排序·非疗效
面向新兴过继性细胞治疗的基于 PCR 的细胞动力学与生物分布分析展望
Perspectives on PCR-Based Cellular Kinetics and Biodistribution Analysis for Emerging Adoptive Cell Therapies.
47.0分
★★★☆☆
站内排序·非疗效
orvacabtagene autoleucel 体液免疫原性的表位定位显示 IgM 应答对 CAR-T 细胞动力学影响极小
Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.
38.5分
★★☆☆☆
站内排序·非疗效
复发/难治性多发性骨髓瘤的 CAR-T 细胞治疗及土耳其的可及性
CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey.
33.1分
★☆☆☆☆
站内排序·非疗效